| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including cancer cell proliferation pathways, inflammatory mediators, and pain signaling pathways. Deoxylimonin exhibits anti-proliferative activity against breast cancer cells. The compound's anticancer activity is attributed to its ability to inhibit cancer cell proliferation and induce apoptosis in preclinical models. Deoxylimonin also exhibits anti-inflammatory effects by modulating inflammatory mediators and signaling pathways. Its analgesic activity suggests interactions with pain signaling pathways. As a limonoid, the compound may also have antioxidant activity by scavenging free radicals and reducing oxidative stress.
|
|---|---|
| ln Vitro |
Treatment with deoxylimonin (0-90 μg/mL, 48 h) inhibits the proliferation of breast cancer cells[2].
Deoxylimonin shows anti-proliferative activities against breast cancer cells. The compound exhibits notable bioactivities including anticancer, antioxidant, and anti-inflammatory effects. It has been shown to inhibit cancer cell proliferation and induce apoptosis in preclinical models. Deoxylimonin derivatives have been reported to show better anticancer, analgesic, and anti-inflammatory activity than the lead compound. The compound's antiproliferative activity makes it of interest for cancer therapy research, particularly for breast cancer. Its anti-inflammatory and antioxidant properties suggest potential applications in metabolic disease management and functional food development. |
| ln Vivo |
In vivo antinociception effects of deoxylimonin (oral administration; 70 mg/kg; once) are demonstrated[1].
Deoxylimonin is orally active, making it suitable for in vivo administration. In vivo studies have demonstrated its anti-proliferative activities against breast cancer cells. The compound has been studied in preclinical models for its anticancer, anti-inflammatory, and analgesic effects. Its derivatives show even better activity than the parent compound. Due to its potential therapeutic properties, deoxylimonin is being studied for applications in cancer therapy, metabolic disease management, and as a natural antioxidant in functional food development. |
| Enzyme Assay |
Non-cell-based assays for deoxylimonin include enzyme inhibition studies to assess its effects on specific targets involved in cancer cell proliferation, inflammation, and pain signaling. Antioxidant activity is assessed using DPPH, ABTS, or FRAP assays. Anti-inflammatory activity is measured by inhibition of COX-2, LOX, or cytokine production in enzyme assays. For compound characterization, standard analytical methods including HPLC, NMR, and mass spectrometry are used to confirm identity and purity. Physicochemical properties such as solubility and stability are determined using standard protocols.
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: MDA-MB-435 and MCF-7 cells Tested Concentrations: 0-90 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated IC50 values of 0.78 μg/mL and 2.50 μg/mL for MDA-MB-435 and MCF-7 cells, respectively. Cell-based assays for deoxylimonin use various cancer cell lines, particularly breast cancer cells, to assess its anti-proliferative activity. Cells are cultured in appropriate medium and treated with deoxylimonin at various concentrations. Cell viability is measured using MTT, CCK-8, or SRB assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining, caspase activity assays, and detection of apoptotic markers by Western blot. For anti-inflammatory studies, macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and treated with the compound, and inflammatory mediators are measured. |
| Animal Protocol |
Animal/Disease Models: Mice injected with acetic acid[1]
Doses: 70 mg/kg Route of Administration: Oral administration; 70 mg/kg; once Experimental Results: demonstrated the antinociception efficacy (writhing inhibition rate: 24.61%). In vivo studies of deoxylimonin have been conducted in preclinical models. The compound is orally active and has been evaluated in animal models of cancer, inflammation, and pain. For anticancer studies, mouse xenograft models bearing breast cancer cells are used. The compound is administered orally, and tumor volume is measured over time. Tumor tissues are collected for histopathological examination and biomarker analysis. For anti-inflammatory studies, carrageenan-induced paw edema models are used. For analgesic studies, pain models such as the hot plate test or formalin test are used. |
| ADME/Pharmacokinetics |
Deoxylimonin has a molecular formula of C₂₆H₃₀O₇ and a molecular weight of approximately 454.51 g/mol. The compound is orally active. It is a triterpenoid compound found in grapefruit seeds. As a limonoid, it is expected to be lipophilic and soluble in organic solvents. The compound should be stored under recommended conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for deoxylimonin are limited. As a natural product from grapefruit seeds, it is generally considered to have low toxicity. However, comprehensive toxicological studies have not been reported. The compound exhibits anti-proliferative activity against cancer cells, indicating biological activity at certain concentrations. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References |
|
| Additional Infomation |
Deoxylimonene is a steroidal lactone. It has been reported that deoxylimonene is found in citrus fruits (Citrus maxima), and relevant data is available for reference.
Deoxylimonin (NSC 314317) is an orally active triterpenoid limonoid compound isolated from grapefruit seeds. Limonoids are a class of triterpenoid compounds found in citrus fruits and other plants, known for their diverse biological activities including anticancer, antioxidant, and anti-inflammatory effects. Deoxylimonin shows anti-proliferative activities against breast cancer cells, and its derivatives have been reported to show better anticancer, analgesic, and anti-inflammatory activity than the parent compound. The compound is being studied for its potential applications in cancer therapy, metabolic disease management, and as a natural antioxidant in functional food development. It is for research use only. |
| Molecular Formula |
C26H30O7
|
|---|---|
| Molecular Weight |
454.51
|
| Exact Mass |
454.199
|
| CAS # |
989-23-1
|
| PubChem CID |
100026
|
| Appearance |
White to off-white solid
|
| Density |
1.32g/cm3
|
| Boiling Point |
660.6ºC at 760 mmHg
|
| Melting Point |
323 - 325 °C
|
| Flash Point |
353.3ºC
|
| Index of Refraction |
1.591
|
| LogP |
3.926
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
968
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C2CC(=O)C3(C(C24COC(=O)CC4O1)CCC5(C3=CC(=O)OC5C6=COC=C6)C)C)C
|
| InChi Key |
QUTATOGBENCRSS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H30O7/c1-23(2)16-9-18(27)25(4)15(26(16)13-31-20(28)11-19(26)33-23)5-7-24(3)17(25)10-21(29)32-22(24)14-6-8-30-12-14/h6,8,10,12,15-16,19,22H,5,7,9,11,13H2,1-4H3
|
| Chemical Name |
18-(furan-3-yl)-9,9,13,19-tetramethyl-4,8,17-trioxapentacyclo[11.8.0.02,7.02,10.014,19]henicos-14-ene-5,12,16-trione
|
| Synonyms |
Deoxylimonin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (220.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2002 mL | 11.0009 mL | 22.0017 mL | |
| 5 mM | 0.4400 mL | 2.2002 mL | 4.4003 mL | |
| 10 mM | 0.2200 mL | 1.1001 mL | 2.2002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
